| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
m-Iodobenzylguanidine (MIBG) targets the norepinephrine transporter (NET), a transmembrane protein responsible for the reuptake of norepinephrine from the synaptic cleft. The guanidine group mimics norepinephrine, allowing it to be recognized and transported into adrenergic neurons and neuroendocrine cells. Upon intracellular accumulation, it is taken up into the granules of adrenal medullary chromaffin cells and pre-synaptic granules of adrenergic neurons. Radiolabeled MIBG is used for diagnostic imaging (¹23I-MIBG) and radionuclide therapy (¹3¹I-MIBG) of neuroendocrine tumors.
|
|---|---|
| ln Vitro |
In vitro, m-Iodobenzylguanidine (MIBG) is a ligand with high affinity for the norepinephrine transporter (NET). As a norepinephrine analog, it is specifically taken up by cells expressing NET, such as neuroblastoma, pheochromocytoma, and carcinoid tumor cells. The compound itself is not typically evaluated in enzyme inhibition assays; its activity is assessed by measuring cellular uptake (e.g., using radiolabeled ¹2⁵I-MIBG) or by competition with norepinephrine in NET-expressing cells (e.g., SK-N-SH neuroblastoma cells). Specific IC₅0 for NET binding is not detailed.
|
| ln Vivo |
In vivo, radiolabeled m-Iodobenzylguanidine (MIBG) is used as an imaging agent in diagnostic imaging and radionuclide studies of neuroendocrine tumors. ¹23I-MIBG is used for scintigraphy to detect primary and metastatic lesions, while ¹3¹I-MIBG is used for targeted radionuclide therapy. ¹2⁴I-MIBG is used for PET imaging. The compound is taken up by NET-expressing tumors, providing diagnostic and therapeutic utility. As a non-radiolabeled reference standard, it is used in analytical studies.
|
| Enzyme Assay |
In vitro NET binding assay: The binding affinity of m-Iodobenzylguanidine to human NET can be assessed using a radioligand binding assay. Membranes from cells expressing recombinant human NET are incubated with [3H]-nisoxetine (a high-affinity NET ligand) and varying concentrations of unlabeled m-Iodobenzylguanidine (0.1 nM to 100 uM) in binding buffer. After incubation at 25degC for 60 min, bound radioactivity is separated by filtration, and the IC₅0 is calculated. Ki is determined using the Cheng-Prusoff equation. For cellular uptake, SK-N-SH cells are incubated with ¹2⁵I-MIBG (0.1-10 uM) with or without excess unlabeled MIBG, and cell-associated radioactivity is measured.
|
| Cell Assay |
In vitro cellular uptake assay: SK-N-SH (human neuroblastoma) or PC12 (rat pheochromocytoma) cells are seeded in 24-well plates (2×10⁵ cells/well) and cultured for 24 hours. The cells are incubated with a trace amount of ¹2⁵I-m-Iodobenzylguanidine (0.1-1 uM) in uptake buffer (25 mM HEPES, pH 7.4, containing 150 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 1.2 mM KH2PO4, and 10 mM D-glucose) at 37degC for 30-60 min. For competition studies, unlabeled m-Iodobenzylguanidine (0.1-100 uM) is co-incubated. The cells are washed with ice-cold PBS, lysed in 0.5 M NaOH, and the radioactivity is measured in a gamma counter. Cellular uptake is expressed as pmol/10⁶ cells or as a percentage of control.
|
| Animal Protocol |
Neuroblastoma xenograft mouse model: Female athymic nude mice (6-8 weeks old) are subcutaneously inoculated with 5×10⁶ SK-N-SH neuroblastoma cells in 0.1 mL PBS/Matrigel (1:1). When tumors reach ~100-150 mm3, mice are randomized into groups (n=5-6/group). For imaging studies, ¹23I- or ¹2⁴I-m-Iodobenzylguanidine (10-37 MBq) is injected intravenously (tail vein). At 4, 24, and 48 hours post-injection, mice are anesthetized, and static planar images are acquired using a gamma camera or micro-SPECT/CT. For ¹3¹I-MIBG therapy studies, mice are administered 10-50 MBq of ¹3¹I-MIBG intravenously. Tumor volume is measured every 2-3 days, and body weight is monitored weekly. Survival is assessed by Kaplan-Meier analysis.
|
| ADME/Pharmacokinetics |
Following intravenous administration of radiolabeled MIBG, the compound is rapidly cleared from the bloodstream. It is taken up by neuroendocrine cells expressing NET. The elimination half-life in plasma is approximately 1-2 hours. Unbound MIBG is excreted primarily in the urine (50-80% within 24 hours). The absorbed dose of radiation to the tumor depends on the tumor volume, uptake, and retention time. For ¹3¹I-MIBG, the effective half-life in the tumor is approximately 2-3 days. The non-radiolabeled m-Iodobenzylguanidine is used as a reference standard for PK studies.
|
| Toxicity/Toxicokinetics |
For m-Iodobenzylguanidine, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). The compound is not for human use; it is for research use only. Handling of radiolabeled forms requires appropriate radiation safety measures.
|
| References | |
| Additional Infomation |
m-Iodobenzylguanidine (MIBG; Iobenguane; CAS# 80663-95-2) is a research-grade norepinephrine transporter (NET) ligand. It is not an FDA-approved drug itself, but radiolabeled forms are used in diagnostic imaging (¹23I-MIBG) and as a therapeutic agent (¹3¹I-MIBG) for neuroendocrine tumors. The non-radiolabeled compound is used as a reference standard in research. For research use only, not for diagnostic or therapeutic applications. Storage: powder at -20degC, protected from light.
|
| Molecular Formula |
C8H10IN3
|
|---|---|
| Molecular Weight |
275.09
|
| Exact Mass |
274.992
|
| CAS # |
80663-95-2
|
| Related CAS # |
m-Iodobenzylguanidine sulfate
|
| PubChem CID |
60860
|
| Appearance |
Solid powder
|
| Melting Point |
0°C
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
166
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC(=C1)I)CN=C(N)N
|
| InChi Key |
PDWUPXJEEYOOTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10IN3/c9-7-3-1-2-6(4-7)5-12-8(10)11/h1-4H,5H2,(H4,10,11,12)
|
| Chemical Name |
2-[(3-iodophenyl)methyl]guanidine
|
| Synonyms |
m-Iodobenzylguanidine; MIBG; Iobenguane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~363.52 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6352 mL | 18.1759 mL | 36.3517 mL | |
| 5 mM | 0.7270 mL | 3.6352 mL | 7.2703 mL | |
| 10 mM | 0.3635 mL | 1.8176 mL | 3.6352 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
